John Sweeney v. Alcon Laboratories
Opinion
NOT PRECEDENTIAL
UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT
No. 20-2066
JOHN M. SWEENEY; REGINA SWEENEY, Appellants
v.
ALCON LABORATORIES; EASTMAN KODAK CO.;
ABC CORPORATION 1–10, a series of fictitious corporations;
JOHN DOES 1–5, a series of fictitious names
On Appeal from the United States District Court for the District of New Jersey (D.C. No. 2:16-cv-04860)
District Judge: Honorable Esther Salas
Argued: March 24, 2021
Before: HARDIMAN, GREENAWAY, JR., and BIBAS, Circuit Judges
(Filed: April 20, 2021)
Gary M. Meyers, I [ARGUED] 35 West Main Street Suite 106 Denville, NJ 07834 Counsel for Appellants
Eric J. Ward [ARGUED] Jeffrey J. Harradine Ward Greenberg Heller & Reidy 1800 Bausch & Lomb Place Legacy Tower Rochester, NY 14604
Amy L. Hansell Daniel M. Young Ward Greenberg Heller & Reidy 701 East Gate Drive Suite 220 Mount Laurel, NJ 08054 Counsel for Appellee
OPINION*
GREENAWAY, JR., Circuit Judge.
The discharge of claims in bankruptcy applies with no less force to claims that are meritorious, sympathetic, or diligently pursued. Though the result may chafe one’s innate sense of fairness, not all unfairness represents a violation of due process.
John Sweeney’s symptoms first manifested in 2009. In 2014, he was diagnosed with adhesive arachnoiditis. It was not until 2015 that he identified a likely source of his injuries: his 1975 exposure to a product called Pantopaque, whose harmful ingredient (iophendylate) Kodak allegedly had manufactured.
By the time Mr. Sweeney ascertained this alleged causal connection, Kodak had undergone reorganization pursuant to chapter 11 of the Bankruptcy Code. As part of this
*
This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does not constitute binding precedent.
process, prepetition claims against Kodak (such as those brought by Mr. Sweeney and Regina Sweeney, his wife) had been discharged.
The Sweeneys assert that the discharge of their claims was not effective because Kodak had not complied with the dictates of due process. They argue that Kodak’s notice of the deadline for filing proofs of claim (the “claims bar date”) should have included language announcing that persons injured as a result of Pantopaque exposure might have claims against Kodak. However, based on the facts pleaded in the Fifth Amended Complaint, requiring such language here would work a dramatic expansion of a bankruptcy debtor’s onus with respect to providing notice to unknown creditors.
The District Court correctly found that Kodak provided sufficient notice to satisfy due process. We will affirm.1 I. Background2 In 1975, fifteen-year-old Mr. Sweeney sustained significant injuries while playing football. During his treatment, physicians injected Pantopaque, a medical-imaging dye product, into his spinal canal. Kodak manufactured iophendylate, a chemical component of Pantopaque.
Articles in medical journals had warned as early as 1945 that dyes used in Pantopaque were linked to a severely debilitating condition known as adhesive
1 The District Court had jurisdiction pursuant to 28 U.S.C. § 1332. This Court has jurisdiction pursuant to 28 U.S.C. §§ 158(d)(1) and 1291(3). 2 Because the District Court dismissed the Sweeneys’ claims pursuant to Federal Rule of Civil Procedure 12(b)(6), we accept the facts pleaded in the Fifth Amended Complaint as true. We consider only the facts pleaded in the operative complaint or amenable to judicial notice. Sands v. McCormick, 502 F.3d 263, 268 (3d Cir. 2007).
arachnoiditis, and in 1969 the FDA requested that Pantopaque’s distributor add specific cautionary language to that effect to its products. Yet the warning label used on Pantopaque in 1975 did not include such language and instead minimized the product’s risks (though it did contain the phrase “severe arachnoiditis”).
As of September 1976, Mr. Sweeney enjoyed a full recovery from his football injuries, but beginning in 2009, he began to experience increasing lower extremity weakness, numbness, clumsiness, and difficulty walking, resulting in increased falls. By 2013, he had been forced to relocate his bed to the lower floor of his home. He submitted to medical testing beginning in 2009 and was diagnosed with advanced adhesive arachnoiditis in August 2014. This prompted him to search for the cause of his arachnoiditis, and an internet search revealed a possible causal link to his exposure to Pantopaque decades earlier. In late 2015, by which time Mr. Sweeney had been diagnosed with end-stage adhesive arachnoiditis, a neurosurgeon confirmed that his exposure to Pantopaque had likely caused his progressive loss of lower extremity function.
In 2012, before Mr. Sweeney had received a diagnosis, Kodak filed a voluntary petition with the Bankruptcy Court of the Southern District of New York (the “Bankruptcy Court”) under chapter 11 of Title 11 of the United States Code. Pursuant to the Bankruptcy Court’s directives, Kodak first published notice of the deadline for filing proofs of claim in the National Edition of The New York Times and in the Democrat and Chronicle in Kodak’s home base of Rochester, New York. It later published notice of the
confirmation hearing in USA Today; The Wall Street Journal, National Edition; and the Democrat and Chronicle.
On August 23, 2013, the Bankruptcy Court confirmed Kodak’s plan of reorganization (the “Bankruptcy Plan”). The Bankruptcy Plan discharged and terminated all claims against Kodak, known or unknown, and enjoined the commencement or prosecution of any claims or causes of action so discharged. The Bankruptcy Court’s Confirmation Order contained a similar injunction.
The Sweeneys commenced this personal injury lawsuit against Kodak and its co-
defendants (which are not party to this appeal) in 2016. In 2018, Kodak moved to dismiss the claims against it pursuant to Sections 524 and 1141(d)(1) of the Bankruptcy Code; the Bankruptcy Court’s August 23, 2013 order confirming Kodak’s Bankruptcy Plan; and “the [District] Court’s inherent judicial powers.” App. 34a. The District Court treated the motion as a motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6).
The District Court granted the motion to dismiss the claims against Kodak, holding that “under either Second or Third Circuit law, Plaintiffs[’] claims must be dismissed because, for unknown creditors, notice by publication was sufficient to satisfy due process.” Sweeney v. Lafayette Pharm., Inc., 2020 WL 2079283, at *2 (D.N.J. Apr. 30, 2020). The District Court found that the factors set forth by this Court in dicta in Jeld-Wen, Inc. v. Van Brunt (In re Grossman’s Inc.), 607 F.3d 114, 127–28 (3d Cir. 2010) (en banc), bolstered the case for discharge. In assessing these factors, it noted that facts pertaining to other Pantopaque-related lawsuits were “not properly before the Court
at the motion to dismiss stage”; while it “acknowledge[d] that discovery could allow it to do a more fulsome analysis,” it found that the record was sufficient for it to decide the issue. Sweeney, 2020 WL 2079283, at *5 n.6.
II. Discussion3 Section 1141(d)(1)(A) of the Bankruptcy Code provides that the confirmation of a reorganization plan “discharges the debtor from any debt that arose before the date of such confirmation,” notwithstanding whether “the holder of such claim has accepted the plan.” 11 U.S.C. § 1141(d)(1)(A). Pursuant to 11 U.S.C. § 524(a)(2), a discharge “operates as an injunction against the commencement or continuation of an action, the employment of process, or an act, to collect, recover or offset any such debt as a personal liability of the debtor, whether or not discharge of such debt is waived.” These provisions were echoed in the Plan and Confirmation Order at issue here.
Free access — add to your briefcase to read the full text and ask questions with AI
John Sweeney v. Alcon Laboratories (John Sweeney v. Alcon Laboratories) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.